ImmuSAFE™ COVID+ biochip test - The world's first multi-antigen, multi-domain, fully quantitative COVID-19 serology test.

The ImmuSAFE™ biochip test enables the determination of the target epitopes, titres and Ig class/sub-class (IgG, IgA, IgM; IgG1-4) of antibodies produced across all stages of COVID-19 infection, from initial exposure, disease development, post-recovery or post-vaccination. lmmuSAFE™ can also enable quantitative assessment of patient response in vaccination trials, including differentiation of whether observed antibody responses are due directly to the vaccine or to prior SARS-CoV-2 exposure.

A lab-based serology test, ImmuSAFE™ utilises Sengenics’ patented KREX™ protein folding technology ensuring that viral antigens attached to the surface are correctly folded and functional, therefore preserving all conformational and linear antibody binding sites. Multiple domains of SARS-CoV-2 Nucleocapsid and Spike proteins including both full-length and numerous truncated versions are used in the tests.

Key applications are vaccine clinical trials and seroprevalence studies. Read more at [ Ссылка ]

свернуть